anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
PURPOSE:To obtain a dental impression material, consisting of ethylene-vinyl acetate copolymer and an oil and having characteristics of being readily flowable at a temperature for collecting an impression, sufficiently retaining the shape below about the bodily temperature and fixing as an elastomer. CONSTITUTION:A dental impression material consisting of 20-80wt.% ethylene- vinyl acetate copolymer (EVA resin) and 80-20wt.% oil (e.g., cotton seed oil, coconut oil, whale oil, beef tallow oil, mineral oil or synthetic oil), and, as necessary, an additive (e.g., waxes or inorganic and organic filler). The vinyl acetate content of the EVA resin is preferably 20-50wt.%. The above-mentioned impression material is inexpensive with affinity for mucosal surfaces of the oral cavity and gypsum and can be readily used simply by, e.g., extrusion from a tube, without requiring skilled techniques. The accuracy in the reproducibility of tissue details in the oral cavity is high and sharp without any influence of exudates in the oral cavity. Furthermore, a change with time is not caused, since water is not contained.
Each of the ten sessions was composed of 45 minutes of balance exercises, each treatment being followed by a 15-min final phase of lower limb stretching, performed with the assistance of a physiotherapist. Sessions were repeated two or three times a week, with at least one rest day between one session and the next, over four successive weeks. Each patient was treated on-phase, at the same time of the day across sessions.
RIPC was induced with 3 cycles of 5 minutes of ischaemia and 5 minutes of reperfusion on the upper arm. By using blood pressure cuff inflation, patients in the RIPC group were exposed to a pressure 50 mmHg higher than the systolic radial artery pressure baseline.
Deep Brain Stimulation (DBS) is a promising therapy for Parkinson's disease (PD). Whether DBS is superior to comprehensive best medical therapy or whether some patients or symptoms respond better to DBS in one area of the brain or the other is currently not known. The goals of this project are to compare the effectiveness of DBS and comprehensive medical therapy as treatments for PD, and to compare bilateral DBS at 2 areas of the brain--the subthalamic nucleus (STN) and the globus pallidus (Gpi)--to determine the most effective brain site for surgical intervention In this prospective, randomized, multi-center trial, 316 patients will be enrolled at 13 centers over four and a half years. Patients will initially be randomized to immediate surgery (DBS) or to 6 months of "best medical therapy." BMT patients will then proceed into the surgical phase of the trial. The DBS site (STN or GPi) will be assigned on a random basis at the time the patient enters the surgical phase of the trial. Patients will be followed for two years post surgery (24-30 months). Effective 08/05/05, randomization to the BMT arm has been discontinued since the study has sufficient information to compare the outcomes of DBS and BMT patients at 6 months. The findings will be critically important in establishing the optimal surgical treatment of the disabling symptoms of PD.
Mild and asymptomatic hypercortisolism has been described to be associated with increased prevalence of chronic complications of cortisol excess, such as osteoporosis, hypertension, type 2 diabetes (T2D) and obesity and with increased mortality. In patients with osteoporosis, hypertension, T2D or obesity, this form of hypercortisolism may remain occult (hidden hypercortisolism, HidHyCo), until its presence is suspected on the basis of particular characteristics of the underlying diseases. The HidHyCo prevalence in the general population is estimated to be 0.2-2%, but it has been suggested to be even higher (up to 10%) in some specific populations as for example in patients T2D. Data regarding the prevalence of HidHyCo in obese populations are limited, Therefore, the issue of which diabetic or obese patient has to be screened for HidHyCo has recently become a widely debated topic. Therefore, the aims of the present study protocol are to assess: i) the HidHyCo prevalence in a sample of T2D patients and the clinical characteristics more frequently associated with the HidHyCo presence; ii) the HidHyCo prevalence in an adequate sample of obese patients without T2D and the clinical characteristics more frequently associated with the HidHyCo presence.

All T2D and obese-without T2D patients between 18 and 75 years of age, consecutively referred to the out-patient clinics for Diabetes and Obesity of our center will be assessed for possible inclusion. At the enrolment in all patients anthropometric e biochemical variables will be recorded. At the enrolment we will evaluate cortisol levels after dexamethasone suppression test (F-1mgDST) in all T2D and obese-without T2D patients, who have been included in the study and who have given the informed consent to participate in the study. In all subjects with F-1mgDST \>1.8 μg/dL, cortisol levels after two-day low dose (2 mg/day) dexamethasone suppression test (F-2mgx2dDST) will be performed. Patients with F-2mgx2dDST above \>1.8 μg/dL will be considered affected with possible HidHyCo and will be studied following the available guidelines for the diagnosis of hypercortisolism.
Hyperosmolar eye drops are lubricating eye drops with 5% of sodium chloride. Hyperosmolar eye drops are thought to temporarily deswell the cornea.

During morning hours, patients with Fuchs' endothelial corneal dystrophy (FECD) typically report poor vision and disturbing glare because of corneal edema. To improve vision in advanced stages of the disease, corneal endothelial transplantation has become the treatment of choice. Many patients with Fuchs' endothelial corneal dystrophy (FECD) use hyperosmolar eye drops before transplantation. At present, it is unclear, how much hyperosmolar eye drops help reducing corneal edema in Fuchs' endothelial corneal dystrophy (FECD). Based on our previous work that determined the amount of additional corneal edema in the morning in patients with Fuchs' endothelial corneal dystrophy (FECD), the investigators will assess if hyperosmolar eye drops speed up the deswelling process.
Each participant will wear 21 surgical face masks corresponding to the follow-up days in the randomized clinical trial, as well as one closed face shield. Additionally, each participant will receive an educational intervention (video).
Participants receive lenvatinib 12 mg (for participants with screening body weight ≥60 kg) or 8 mg (for participants with screening body weight \<60 kg) orally once a day (QD) plus pembrolizumab 200 mg by intravenous (IV) infusion on Day 1 of each 21-day cycle (Q3W). Pembrolizumab will be administered for up to 35 cycles (approximately 24 months). Lenvatinib will be administered until progressive disease or unacceptable toxicity.
The invention provides a ceftezole sodium pharmaceutical composition powder injection and relates to the field of pharmaceutical preparations and a preparation method thereof. The ceftezole sodium pharmaceutical composition powder injection mainly solves the problem that the existing ceftezole sodium and metronidazole single-component preparations have large use amounts, and have poor effects and side effects after combination. The ceftezole sodium pharmaceutical composition comprises ceftezole sodium and metronidazole lipid microspheres, wherein based on metronidazole weight, a weight ratio of the ceftezole sodium to the metronidazole lipid microspheres is in a range of (100: 4) to (100: 15). The ceftezole sodium pharmaceutical composition is processed into the ceftezole sodium pharmaceutical composition powder injection. An aqueous solution of the ceftezole sodium pharmaceutical composition has a pH value of 4.5-6.5. The ceftezole sodium pharmaceutical composition powder injection has high curative effects and reduces a metronidazole use amount by above 80% so that metronidazole toxic and side effects especially on the digestive tract such as nausea, vomit, inappetence, abdominal cramp and neurotoxicity are greatly reduced and an adverse reaction occurrence rate is reduced.
Overweight and obesity are major health problems, affecting over two-thirds of US adults. Commercially available Internet-based weight loss programs are currently used by millions of overweight/obese individuals in the U.S, but weight losses are often poor, likely because these products on the whole do not incorporate empirically validated behavioral weight loss strategies that have been researched for over 40 years. Similarly, the weight losses obtained via research-based online weight loss programs are about half the size of those obtained via in-person treatment, likely because of the lack of (1) "hands-on" training in behavioral weight control strategies, and (2) support and guidance from group leaders and peers, both of which are hallmarks of traditional in-person treatment. The goal of this application is to improve commercial Internet -delivered behavioral obesity treatments by developing a virtual reality (VR) system that can be integrated into existing Internet weight control programs, such as Weight Watchers Online. The VR system will allow users to experience learning, implementing, and mastering behavioral weight control strategies in controlled virtual settings. The VR system will: (a) increase awareness of barriers to weight control behaviors, (b) teach skills to cope with these barriers, (c) build confidence using these skills, and (d) increase commitment to using these skills in real-world situations. The design of the VR System is based on Social Cognitive Theory, which states that health behaviors are learned by observing and imitating peers and role models, and by receiving social reinforcement. A randomized controlled trial (RCT) will be conducted with N = 125 participants to test the efficacy of 4 scenarios for improving weight losses obtained in a popular paid commercial weight loss program (Weight Watchers Online) over 6 months.
PURPOSE: Speech motor skill is refined over the course of practice, which is commonly reflected by increased accuracy and consistency. This research examined the relationship between auditory-perceptual ratings of word accuracy and measures of speech motor timing and variability at pre- and posttreatment in children with childhood apraxia of speech (CAS). Furthermore, the degree to which individual patterns of baseline probe word accuracy, receptive language, and cognition predicted response to treatment was explored.
METHOD: Probe data were collected from seven children with CAS (aged 2;5-5;0 [years;months]) who received 6 weeks of Dynamic Temporal and Tactile Cueing (DTTC) treatment. Using a multidimensional approach to measuring speech performance, auditory-perceptual (whole-word accuracy), acoustic (whole-word duration), and kinematic (jaw movement variability) analyses were conducted on probe words produced pre- and posttreatment. Standardized tests of receptive language and cognition were administered pretreatment.
RESULTS: There was a negative relationship between auditory-perceptual measures of word accuracy and movement variability. Higher word accuracy was associated with lower jaw movement variability following intervention. There was a strong relationship between word accuracy and word duration at baseline, which became less robust posttreatment. Furthermore, baseline word accuracy was the only child-specific factor to predict response to DTTC treatment.
CONCLUSIONS: Following a period of motor-based intervention, children with CAS appeared to refine speech motor control in conjunction with improvements in word accuracy. Those who demonstrated the poorest performance at treatment onset displayed the greatest degree of gains. Taken together, these results reflect a system-wide change following motor-based intervention.
Participants, along with support persons, will complete 12 weekly sessions of the BeatIt-MV intervention. The support person will complete an initial session before commencement of the 12 weekly sessions.
PURPOSE:To obtain a new subject compound available from cultured mixture of a fungus belonging to the genus Streptomyces and capable of producing a new compound TG-488A, exhibiting a strong antimicrobial activity against eumycetes causing opportunistic mycosis and useful as an antimycotic agent, etc. CONSTITUTION:This new compound TG-488A consists of a new pentaene compound of the formula and has strong antimicrobial activity against eumycetes causing opportunistic mycosis and is useful as a new antimycotic agent. The compound is obtained by inoculating a microorganism belonging to the genus Streptomyces and producing a new compound TG-488A [e.g. Streptomyces sp. T-920488 strain (FERM P-14140), etc.] into a medium, culturing the microorganism at 27 deg.C for 14 day, separating the microbial cell by centrifugal separation or filtration, etc., extracting the separated microbial cell with a solvent such as acetone or methanol, distilling the solvent in the extracted liquid away and purifying the resultant residue with absorption chromatography, high- performance liquid chromatography, etc.
Participants completed a total of 24 sessions that were pre-programmed and led by a certified instructor (CrossFit Level 2), which lasted up to 60 minutes in duration. The first two class periods were structured as an introduction to common movements used in high-intensity functional training (HIFT; e.g., squats, deadlift, press, jerks, barbell, dumbbell, and medicine ball cleans, pullups, kettlebell swings, among others). No scheduled workouts were given on days 1 and 2. Beginning on day 3 each HIFT class consisted of 10-15 minutes of stretching and warmup, 10-20 minutes of instruction and practicing techniques and movements, and 5-30 minutes for the workout of the day, performed at vigorous intensity, relative to each person's ability and fitness level. All weights and movements were individually prescribed and recorded for each participant.
The Fagaceae, a plant family with a wide distribution and diverse adaptability, has garnered significant interest as a subject of study in plant speciation and adaptation. Meanwhile, certain Fagaceae species are regarded as highly valuable wood resources due to the exceptional quality of their wood. In this study, we present two high-quality, chromosome-scale genome sequences for Quercus sichourensis (848.75 Mb) and Quercus rex (883.46 Mb). Comparative genomics analysis reveals that the difference in the number of plant disease resistance genes and the nonsynonymous and synonymous substitution ratio (Ka/Ks) of protein-coding genes among Fagaceae species are related to different environmental adaptations. Interestingly, most genes related to starch synthesis in the investigated Quercoideae species are located on a single chromosome, as compared to the outgroup species, Fagus sylvatica. Furthermore, resequencing and population analysis of Q. sichourensis and Q. rex reveal that Q. sichourensis has lower genetic diversity and higher deleterious mutations compared to Q. rex. The high-quality, chromosome-level genomes and the population genomic analysis of the critically endangered Q. sichourensis and Q. rex will provide an invaluable resource as well as insights for future study in these two species, even the genus Quercus, to facilitate their conservation.
A method for imparting non-comedogenicity to a cosmetic composition which comprises incorporating into a cosmetic composition a predetermined amount of an ester of ricinoleic acid to act as an emollient, said ricinoleic acid ester having formula (I), wherein R1? is a straight or branched chain alkyl or alkenyl group having between one and 40 carbon atoms; R2? is hydrogen; (Ia?) connected to a straight or branched chain alkyl or alkenyl group having between one and 40 carbon atoms; or between one and 40 moles ethylene or propylene oxide; and the total molecular weight of R1? and R2? is at least about 150, preferably greater than about 170.
Acute myeloid leukaemia (AML) is a life-threatening malignant blood disorder. Curative treatment requires multiple cycles of intensive chemotherapy. The first cycle, induction, is the most intense and intended to achieve complete disease remission (CR). Induction therapy requires 4-6 weeks of inpatient admission and is associated with extended bed rest and multiple toxicities, leading to physical deconditioning. Regular exercise during induction may reduce declines in physical fitness, leading to improved quality of life (QOL), reduced fatigue, improved tolerance of chemotherapy, and potentially greater survival. Four prior studies of exercise in AML patients undergoing induction have suggested improvements in QOL, fatigue, physical function, and treatment tolerability. However, all 4 studies suffered from major limitations including small sample sizes, design limitations, generalizability concerns, and limited safety information. The investigators conducted a pilot non-randomized study in 35 AML patients and demonstrated feasibility, safety, and potential improvements in QOL, fatigue, and physical fitness outcomes. The investigators now propose a rigorous evaluation of the intervention in a phase II randomized controlled trial (RCT).

Primary objectives include: (1) To determine the efficacy of a supervised mixed-modality exercise program during induction chemotherapy on QOL and fatigue; (2) To determine the efficacy on physical fitness. Our secondary objective is to determine the efficacy on AML treatment tolerability (hospital length of stay, development of sepsis, intensive care unit (ICU) admission, delays in consolidation chemotherapy).
This group is both a control and an experimental group. Indeed, the intervention (i.e., the same as for group 1) is administered but after a second baseline which is held after the completion of the Group 1. This condition will allow to check the specific efficiency of the intervention.
OBJECTIVE: Patients with chronic pain often have sleep disturbances, and many patients receive sleep medications in addition to analgesics. Although there have been scattered reports of negative pain-sleep interactions, only a few reports have investigated the efficacy of sleep medication interventions in patients with chronic pain for improving sleep disturbances and reducing pain. We retrospectively examined whether lemborexant, an orexin receptor antagonist, is effective in improving sleep disturbances and reducing pain in patients with chronic pain. This study was approved by the Ethics Committee of our hospital.
METHODS: The subjects were 26 patients with chronic pain undergoing treatment at our pain clinic between July 2021 and March 2022, who had been diagnosed with insomnia, with an Athens Insomnia Scale (AIS) score of ≥6 and had been started on lemborexant. The AIS score and pain score (Numeric Rating Scale [NRS]) before and after 2 and 4 weeks of starting lemborexant were investigated.
RESULTS: Patients who were already taking other sleep medications, such as benzodiazepines were switched to 5 mg of lemborexant after all the other sleep medications were discontinued. Those who had not yet used sleeping pills were started on 5 mg of lemborexant. During the study course, the dose of lemborexant was adjusted at the discretion of the attending physician, based on improvement of insomnia symptoms and secondary symptoms, such as daytime sleepiness and lightheadedness. The study finally included 21 patients, excluding 5 who could not continue taking lemborexant due to side effects, such as lightheadedness. The AIS scores significantly improved, decreasing from baseline (mean ± standard deviation: 12.5 ± 4.9) to 2 weeks (7.8 ± 3.1) and 4 weeks (5.3 ± 2.9) after the start of lemborexant. No significant difference was observed in the degree of improvement in sleep disturbance between patients with or without previous sleep medications, and there was also no statistically significant improvement in the NRS score before (6.1 ± 2.7) and after 2 weeks (5.5 ± 2.3) and 4 weeks (5.9 ± 2.2) from treatment initiation.
Children aged 3-6 who require nebulizer treatment in the emergency department, along with their families, will first be informed by one of the researchers. Then, children who are randomly assigned to the control group will be treated according to the institution's standard care procedures. The child and their family will be informed immediately before the treatment procedure. During the treatment, the child will be treated using a standard nebulizer mask appropriate for their age, in accordance with the institution's routine care procedures, and the parent will remain with the child throughout the treatment. The child's level of fear will be assessed by both the child and the nurse before and during the treatment. Additionally, the nurse will record the total duration of inhaler treatment and the child's adherence to the treatment.
When annotating a patient's medical or clinical record, an automated annotation system compares aggregated patient data (e.g., historical vital sign data, lab results, patient admission/discharge/transfer information, etc.) and matches events and/or patterns therein to procedure profiles to determine whether a given procedure is required, in progress, or completed. If the probability of procedure necessity or occurrence is above a predetermined threshold, then system inserts an annotation into the clinical record to mitigate a need for a clinician to manually enter the annotation. Alarm parameters are adjusted to reflect a physiological response to the determined procedure, to reduce false alarm triggers. Additionally or alternatively, triggered advisories may be suppressed from the user interface for a time period during which conditions specified in the procedure profile exist, or for a specific period of time following the procedure. In another embodiment, triggered advisories that occur under the specific conditions identified in a procedure profile may be flagged in the patient's medical record with a notification that the suspected procedure is being performed.
The invention provides a traditional Chinese medicine composition for treating herpes zoster, and application and a preparation method thereof in an external medicament. Wherein, the Chinese medicinal composition for treating herpes zoster is prepared from realgar, alum, fructus forsythiae, moutan bark, borneol and rhizoma corydalis. By taking the realgar and the alum which have the effects of detoxifying and drying dampness as monarch drugs, the effects of detoxifying, drying dampness and eliminating turbid pathogen are achieved together. Fructus forsythiae and cortex moutan with effects of clearing away heat and toxic materials, resolving hard mass, relieving swelling, promoting blood circulation, and removing blood stasis are used as ministerial drugs. Borneol with the functions of clearing away heat, relieving pain, eliminating swelling and promoting granulation is used as adjuvant medicine. Rhizoma corydalis with effects of promoting blood circulation, activating qi-flowing and relieving pain is used as guiding drug. The compatibility of the six components is utilized to realize the effects of clearing heat and drying damp, eliminating stagnation and reducing swelling, detoxifying and promoting granulation, activating blood and dissolving stasis, and promoting qi circulation and relieving pain. The preparation method is selected according to different syndromes and skin damage characteristics, and green tea water is respectively used for preparing lotion, sesame oil is used for preparing oil, and Chinese liquor is used for preparing tincture for external use to treat herpes zoster in the blister stage, ulceration stage, and postherpetic neuralgia stage of herpes zoster.